Beacita 60mg - 84 capsules

Product Description

Beacita is indicatedfor weight loss in overweight adults

Indications

Beacita is a weight loss medicine recommended for overweight adults (body mass index, BMI, ≥ 28 kg/m²) and should be taken in conjunction with a moderately hypocaloric, low-fat diet.

Dosage and method of administration

The capsule should be taken with water immediately before, during, or within one hour after main meals.

Adults: The recommended dosage of BEACITA is one 60 mg capsule to be taken three times a day. No more than three 60 mg capsules should be taken in 24 hours. Treatment should not be more than once a day. 6 months.
If patients are unable to lose weight after 12 weeks of treatment with BEACITA, they should consult their doctor or pharmacist. Treatment may need to be stopped.
Diet and exercise are important components of a weight loss program. It is recommended to start a diet and exercise program before starting treatment with BEACITA.
During treatment with orlistat, the patient should follow a nutritionally balanced, moderately hypocaloric diet containing approximately 30% of calories from fat (e.g., in a 2,000 kcal per day diet, this corresponds to <67 g fat). The daily intake of fats, carbohydrates and proteins should be distributed over three main meals.
The diet and physical exercise program should continue even when treatment with BEACITA is stopped.
Paediatric population
Children:It should not be used in children and adolescents under 18 years of age due to insufficient data on safety and efficacy.

Elderly (>65 years): Only limited data are available on the use of orlistat in the elderly. However, since orlistat is only minimally absorbed, no dose adjustment is necessary in the elderly.

Ingredients

Capsule content: Microcrystalline cellulose PH112; Sodium starch glycolate (type A); Colloidal anhydrous silicon; Sodium lauryl sulfate.
Capsule coating: Gelatin; Indigo carmine (E132); titanium dioxide (E171).

Contraindications

• Hypersensitivity to the active substance or to any of the excipients.
• Concomitant treatment with ciclosporin (see section 4.5).
• Chronic malabsorption syndrome.
• Cholestasis.
• Pregnancy (see section 4.6)
• Breastfeeding (see section 4.6)
• Concomitant treatment with warfarin or other oral anticoagulants (see sections 4.6 and 4.7)
• Hepatic and renal impairment: The effects of orlistat in subjects with hepatic and/or renal impairment have not been studied. However, since orlistat is only minimally absorbed, no dose adjustment is necessary in subjects with hepatic and/or renal impairment.

Side effects

Adverse reactions to orlistat are predominantly gastrointestinal and are related to the pharmacological effect of the drug on the inhibition of the absorption of ingested fat.
The gastrointestinal adverse reactions identified in clinical studies with orlistat 60 mg lasting 18 months to 2 years were generally mild and transient. They generally occurred early in the course of treatment (within 3 months) and most patients experienced only one episode. Consumption of a low-fat diet tends to be to reduce the likelihood of developing gastrointestinal adverse reactions (see section 4.4).

Storage instructions

Do not store above 25°C. Store in the original package in order to protect from light and moisture.

Format

84 mg pack